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The success of passive immunization suggests that antibody-based therapies will be effective at controlling malaria.
We describe the development of fully human antibodies specific for Plasmodium falciparum by antibody repertoire
cloning from phage display libraries generated from immune Gambian adults. Although these novel reagents bind
with strong affinity to malaria parasites, it remains unclear if in vitro assays are predictive of functional immunity in
humans, due to the lack of suitable animal models permissive for P. falciparum. A potentially useful solution described
herein allows the antimalarial efficacy of human antibodies to be determined using rodent malaria parasites
transgenic for P. falciparum antigens in mice also transgenic for human Fc-receptors. These human IgG1s cured animals
of an otherwise lethal malaria infection, and protection was crucially dependent on human FccRI. This important
finding documents the capacity of FccRI to mediate potent antimalaria immunity and supports the development of
FccRI-directed therapy for human malaria.
Citation: McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, et al. (2007) The importance of human FccRI in mediating protection to malaria. PLoS Pathog 3(5):
e72. doi:10.1371/journal.ppat.0030072
Introduction
Malaria continues to kill approximately 2–3 million people
each year [1]. The success of passive immunization in humans
and animals suggests that immunoglobulin (Ig)-based thera-
pies could be effective [2,3]. Manipulating antibody (Ab)
genes allows the design of Ig with deﬁned class and speciﬁcity,
targeting protective epitopes on the parasite surface [4,5]. An
appropriate target is the 19-kDa C-terminal region of
merozoite surface protein 1 (MSP119). This polypeptide
displays limited sequence polymorphism possibly because
the structure is constrained by its function [6], is expressed by
all vertebrate asexual life-cycle stages [7], and acts as a major
target of the erythrocyte invasion-inhibitory Ab response in
individuals immune to Plasmodium falciparum malaria [8].
Novel genetic approaches, including linkage-group selection,
have also identiﬁed MSP1 as an important target of immunity
[9].
The mechanisms whereby Ig mediates protective immunity
in malaria are less clear. The importance of Fc-receptor (FcR)
subunits in malaria immunity has been studied in animals
with FcR deletions. Although informative, these gene-deﬁ-
cient mouse models may not always mimic the human
immune condition, due to differences in FcR biology and
an apparent lack of true homologues [5]. Studies examining
the role of FcR in immunity to parasites have made use of
FcRc-chain knockout mice [10,11]. The c-chain, a subunit
common to FccRI, FccRIIIa, FceRI, and FcaRI, is required for
efﬁcient cell surface expression and signal transduction.
Consequently, FcRc/ mice are unable to elicit phagocytosis
or Ab-dependent cell-mediated cytotoxicity reactions
through these receptors. Two recent studies with rodent
malarias in the FcRc/ have proved controversial, with one
study showing a crucial role for FcR-mediated Ab-dependent
phagocytosis in host resistance to blood-stage Plasmodium
berghei XAT infection [10], and another study with Plasmodium
yoelii concluding that the protective effects of Ab probably
arise through FcR-independent mechanisms [11]. However,
these studies ignore two important possibilities. Firstly, there
might be other, as yet unidentiﬁed, FcR involved in the
observed response, and secondly, the a-chain of many FcR
may associate with other signaling proteins other than the
common c-chain. With this in mind, it is interesting to note
that mouse IgG3-opsonized Cryptococcus neoformans can still be
phagocytosed by macrophages from FcRc/ mice [12]. This
effect is probably mediated via an undeﬁned FcR without
requiring c-chain for function because, of the known FcR,
only murine FccRI binds mouse IgG3, as demonstrated by
transfection studies [13]. Secondly, FcRc-chain-deﬁcient mice
were found to express partially functional FccRI in more
recent mouse knockouts [14,15]. It is now known that the c-
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chain of FccRI can mediate MHC class II Ag presentation
without active c-chain signaling [16], and that the a-chain can
interact with Periplakin to control receptor endocytosis and
IgG binding capacity [17]. These potential drawbacks to the
rodent FccRI knockout model led us to investigate the
possibility of using human FcR transgenic mice to investigate
Ab function with relation to malaria.
Antibodies have been shown to be vital for the develop-
ment of protective immunity, and as such they act as
correlates of protection in studies aimed at deﬁning the best
antigens to incorporate into current vaccines. Understanding
which Ab and FcR combination optimally induces immunity
is therefore vital to developing the best vaccines. Surrogate
markers of Ab efﬁcacy currently rely on in vitro assays that
are laborious and difﬁcult to reproduce and it remains
unclear if such in vitro assays are predictive of functional
immunity in humans due to the lack of suitable animal
models permissive for P. falciparum [18,19]. By using rodent
malarias transgenic for P. falciparum antigens in mice also
transgenic for human FcRs, we have created a novel model
that more fully mimics P. falciparum infection in humans,
while providing an alternative to nonhuman primates for
assessing the efﬁcacy of anti–P. falciparum Abs prior to clinical
trials in humans.
Here, we create novel fully human Abs speciﬁc for P.
falciparum MSP119 by Ab repertoire cloning from phage
display libraries generated from malaria-immune Gambian
adults. Using this unique dual transgenic approach, we were
able to show that these human Abs are completely protective
in vivo, and that this effect was crucially dependent on human
FccRI (CD64).
Results
Development of Antibody Repertoire Phage Display
Libraries from Malaria-Exposed Donors
We describe the construction of two phage display libraries
derived from blood donations from malaria-exposed donors.
The combined size of the two libraries (;1.33 109 members)
was sufﬁciently large to anticipate high afﬁnity antibody
fragments (unpublished data) [20]. PCR and BstNI ﬁnger-
printing of 100 randomly selected clones and their sequenc-
ing conﬁrmed that they were derived from a wide range of
different variable gene families (Figure 1A–1B). In additional
experiments to estimate diversity, a number of clones were
randomly sequenced from the unpanned libraries and found
to be very diverse and derived from a wide range of different
V gene families (unpublished data) [20]. Four rounds of
panning with recombinant MSP119-GST yielded scFvs capable
of strong binding to P. falciparum parasites by immunoﬂuor-
escence (IFA) (Figure 1C). Immunoblotting conﬁrmed that
polyclonal scFv from later rounds of panning did bind native
MSP1 from T9/96 and FCB-1-derived P. falciparum merozoites
(Figure 1D–1E). Intriguingly, panning against whole mero-
zoites in which MSP1 processing had been allowed to
proceed, gave almost identical patterns recognizing MSP119
and MSP142 to that seen when libraries were panned on
recombinant proteins. Additionally, the close sequence
similarity between scFvs obtained by panning with either
processed merozoites or recombinant MSP119 suggests that
natural antibody responses to the merozoite after secondary
processing are directed more toward MSP119 than any other
antigen remaining on the merozoite surface.
Twenty individual MSP119-binding scFv clones selected on
the basis of their binding to MSP119-GST by ELISA, their
variety of restriction fragment patterns on BstNI digestion,
and their ability to inhibit the binding of anti–P. falciparum
MSP119 monoclonal antibodies (mAbs) 12.8 and 12.10 in
competition ELISAs (Figure 1F) were sequenced. mAb 12.8
and 12.10 have been shown to inhibit erythrocyte invasion in
vitro by P. falciparum merozoites [21,22]. Of these 20 clones,
six different scFv sequences were found (Figure 2A). None of
the six scFvs inhibited erythrocyte invasion in vitro [20]. We
therefore engineered the most promising scFvs into fully
human antibodies since the presence of the Fc may
potentiate inhibition of erythrocyte invasion, a likely pre-
diction given that Fab and F(ab9)2 fragments of mAb 12.10 do
not retain invasion-inhibitory properties [23]. Intriguingly,
we have recently isolated scFv to other key malaria antigens
from this library, including EBA-175 and EMP1 (unpublished
data).
Development of Two Fully Human IgG1s Recognizing
P. falciparum MSP119
We subcloned the variable genes derived from two
promising scFvs c1 and e9 and linked them to human IgG1
constant domains in expression vectors as previously used to
successfully generate chimeric human anti–P. yoelii MSP119
IgG1s [24]. Both antibodies, now termed JS1 (derived from
phage c1) or JS2 (derived from phage e9), when puriﬁed from
CHO-K1 transfectant culture supernatants contained poly-
peptides of the expected sizes on SDS-PAGE and the
anticipated reactivities with isotype-speciﬁc antibodies (Fig-
ure 3A). JS1 and JS2 recognized a P. falciparum MSP119-GST
fusion protein (Figure 3B), and by indirect IFA, both
antibodies produced a characteristic pattern of MSP1
reactivity in schizonts, merozoites, and ring-stage parasites
from P. berghei parasites transgenic for P. falciparum MSP119
(PbPfM19), but not to the control transgenic line PbPbM19
previously engineered to integrate in an identical manner the
homologous P. berghei MSP119 sequence (Figure 3C) [25]. The
use of P. berghei and P. falciparum MSP119-speciﬁc antibodies
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Author Summary
Malaria rivals HIV and tuberculosis as the world’s most deadly
infection killing a child every 30 seconds. Antibodies and their
receptors (Fc-receptors) have been shown to be vital for the
development of protective immunity, and as such they act as
correlates of protection in studies aimed at defining the best
antigens to incorporate into current vaccines. Understanding
antibody types and Fc-receptors that optimally induce immunity is
therefore vital to developing the best vaccines. Surrogate markers of
antibody efficacy currently rely on in vitro assays that are laborious
and difficult to reproduce. It remains unclear if such in vitro assays
are predictive of functional immunity in humans due to the lack of
suitable animal models permissive for Plasmodium falciparum. Here,
we create a transgenic in vivo mouse model that has significant
advantage over the use of new world primates, the only other
model for human malaria. We demonstrate that this model defines
an Fc-dependent mechanism of parasite destruction that cannot be
assessed in current in vitro assays. The model provides both a test
for therapeutic antibody efficacy prior to clinical trials in humans
and an important tool in malaria vaccine development.
(aPbM19 and aPfM19) allowed conﬁrmation of the genotype
of the transgenic lines while demonstrating that both JS1 and
JS2 colocalize only with aPfM19 detecting reagent (Figure 3C,
merge þ brightﬁeld). This novel rodent malaria model thus
provides an alternative to nonhuman primates for assessing
and monitoring the efﬁcacy of P. falciparum MSP119-based
human antibodies in mice transgenic for human Fc-receptors
[25]. In addition, both JS1 and JS2 bound to the 3D7 P.
falciparum reference strain (Figure 3D).
Importantly, surface plasmon resonance (SPR) analysis
revealed no reduction in afﬁnity for MSP119 for either JS1
or JS2 when compared with mouse mAbs 12.8 and 12.10
(Figure 2B). However, JS2 did have a reduced on-rate and
therefore a lower overall afﬁnity for P. falciparum MSP119
when compared with JS1, a ﬁnding that may explain the
reduced potency seen with JS2 in vivo. Despite comparable
afﬁnities for MSP119, neither JS1 nor JS2 inhibited MSP1
processing when compared to mAb 12.8 (unpublished data,
available on request).
JS1 and JS2 Are Fully Functional Human IgG1 Antibodies
We assessed the ability of these novel reagents to
phagocytose MSP119-coated ﬂuorescent microspheres (Figure
4A). Beads opsonized with JS1 Abs speciﬁc for MSP119 from P.
falciparum could be detected within human neutrophils. The
capacity to ingest these ‘‘pseudomerozoites’’ was enormous
with up to 20 beads being detected in some neutrophils. We
also assessed the ability of these novel reagents to elicit an
oxidative burst and degranulation in human neutrophils
(Figure 4B). When attached to GST-PfMSP119-coated plates at
equimolar concentrations, an epitope matched human IgA1
recently constructed from the same variable genes as in JS1
(unpublished data) was consistently the most efﬁcient at
inducing respiratory bursts, although both JS1 and JS2 were
also very effective. Since uninduced human neutrophils do
Figure 1. Characterization of scFvs Derived from Phage Libraries
Estimation of diversity of library scFv inserts by BstNI digestion. Figure shows restriction digest patterns of 50 randomly selected scFvs from the October
library.
(A) 50 inserts of the VH–VK scFvs amplified by PCR screen from 50 randomly selected colonies.
(B) The same VH–VK scFv inserts after digestion with BstNI. A large number of different digestion patterns are seen, suggesting a high degree of diversity
among the library.
(C–E) Binding of polyclonal scFv from panning rounds 1–4 to P. falciparum by IFA [20]. IFA was carried out using acetone-fixed parasites, and the
polyclonal scFv tested against the T9–96 and FCB-1 strains of P. falciparum at 20 lg/ml [20]. MAb 12.8 was used as a positive control and polyclonal scFv
prepared from the unpanned libraries used as negative controls. Immunoblots of polyclonal scFv from fourth round of panning binding to P. falciparum
strain T9/96 (D) or FCB-1 (E) merozoites [20]. Lane 1, scFv March library unpanned; lane 2, scFv October library unpanned; lane 3–6, scFv from fourth
round of panning with unprocessed merozoites; lane 7–8, scFv from fourth round of panning with processed merozoites; lane 9, scFv from fourth round
of panning with recombinant MSP119-GST; lane 10, scFv D1.3 (anti-hen’s egg lysozyme); lane 11, scFv X509 (anti-MSP133); lane 12, scFv 89.1 (anti-
MSP183); lane 13, mAb 12.8 (anti-MSP142 and MSP119).
(F) Inhibition of binding of mAbs 12.8 and 12.10 to MSP119 by scFvs derived from the fourth round of panning by competition ELISA [20].
doi:10.1371/journal.ppat.0030072.g001
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not express many molecules of FccRI, phagocytosis and
respiratory bursts in this instance most likely occur through
FccRIIA and/or FccRIIIB.
Epitope Mapping of JS1 and JS2 Binding Sites on MSP119
A number of approaches were used in order to identify the
amino acid residues in MSP119 contributing to the binding of
JS1 and JS2. A competition ELISA was designed to determine
whether JS1 or JS2 could compete with mAbs 12.8 or 12.10 for
binding sites on MSP119 (Figure 5). Binding of either JS1 or
JS2 reduced the binding to MSP119 of mAbs 12.8 and 12.10 by
;60% and 30%, respectively, suggesting that JS1 and JS2
compete with mAbs 12.8 and 12.10 for similar epitopes. JS1
and JS2 may therefore be described as blocking antibodies
since they inhibit the binding of invasion inhibitory mAbs.
Intriguingly, the converse experiment with 12.10 and 12.8
failed to inhibit binding of JS1 or JS2, suggesting that the fully
human antibodies may bind MSP119 with a higher afﬁnity
and/or that the epitopes seen are nonidentical but over-
lapping. In order to identify the amino acid residues involved
in JS1 and JS2 binding, we made use of a panel of MSP119
mutants available from a previous study investigating the
binding of inhibitory and blocking mAbs [26]. Binding of Abs
to the modiﬁed proteins was detected by ELISA and SPR
analysis. Table 1 summarizes the effect of 11 single and six
multiple amino acid substitutions on binding by JS1 and JS2
compared with the previously described effects on interac-
tion with mAbs 12.10 and 12.8. Of these, only one amino acid
substitution (Cys28!Trp) completely ablated binding by both
JS1 and JS2. Cys28 forms a disulﬁde bond with Cys12, the
mutation of which (Cys12!Ile) had no affect on binding by
JS1 or JS2 but did completely prevent binding by the mAbs
12.10 and 12.8. Six further mutants had intermediate effects
on binding by JS1 and JS2, with (Arg20!Glu) and (Asn33!Ile)
being particularly prominent since no binding by SPR
analysis was seen when these mutant proteins were passed
over JS1 or JS2 at identical concentrations to wild-type
protein (Figure 6 and Table 1). Three further substitutions at
Lys40, Lys29, and Asn39 only had minor affects on binding. No
differences in gross binding (other than minor differences in
afﬁnity) could be seen to distinguish JS1 from JS2, despite
signiﬁcant variability (20 amino acid substitutions through-
out each VL and VH gene) within the complementarity
determining regions of their respective variable genes (Figure
2A and Table 1). These ﬁndings support our assertion that JS1
and JS2 bind to nonidentical but overlapping residues in the
ﬁrst epidermal growth factor domain of MSP119, in common
with mAbs 12.8 (Figure 6 and Table 1) and 12.10 (for which
the epitope also has a contribution from the second
epidermal growth factor domain).
Figure 2. Sequencing of V Genes and SPR Analysis
(A) Amino acid sequences of MSP119-binding scFvs. Sequences of six selected scFvs obtained by panning phage display libraries with recombinant
MSP119 (C1) or P. falciparum merozoites in which secondary processing had been allowed to proceed (E9). Amino acids in bold represent residues in the
E9 sequence differing to C1.
(B) SPR association and dissociation curves of Ab binding to MSP119 immobilized on a CM5 sensor chip. Abs were injected into flow at time 0 and
replaced with buffer at the point indicated by vertical arrow [24].
doi:10.1371/journal.ppat.0030072.g002
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Figure 3. Characterization of Purified Abs
(A) 5 lg purified anti-MSP119 human IgG1 (JS1) was subjected to SDS-PAGE under nonreducing (lane 1) or reducing (lane 2) conditions on 4%–15%
polyacrylamide gradient gels and stained with Simply Blue or immunoblotted with anti-human IgG-HRP.
(B) Under nonreducing conditions and after transfer to nitrocellulose, the human anti-MSP119 IgG1 (JS1) detects the recombinant GST-MSP119 fusion
protein (lane 3) but not the GST alone control (lane 4). Localization of MSP119 by IFA.
(C) Schizont- and merozoite-stage parasites from the transgenic PbPbM19 and PbPfM19 lines were incubated with human Abs JS1 or JS2 (1:100), rabbit
aPbM19 (1:1,000), or aPfM19 (1:1,000). After incubation with goat anti-rabbit Alexa-conjugated Ig (1:1,000) and FITC-conjugated anti-human IgG Fc
(1:200), slides were washed and mounted in Vectrashield anti-fade. Parasites were visualized by fluorescence microscopy3100 magnification, with the
same fields photographed using filters to detect Alexa and FITC.
(D) JS1 reactive with MSP119 on methanol-acetone-fixed smears of merozoites and erythrocytes infected with P. falciparum (strain 3D7) 340
magnification. JS2 gave similar results. No specific fluorescence was detected with an irrelevant human IgG1 (B10) recognizing MSP119 from P. yoelii
[24].
doi:10.1371/journal.ppat.0030072.g003
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Suppression of Parasitemia by JS1 Is Critically Dependent
on the Presence of Human FccRI
In vivo experiments with P. berghei transgenic for P.
falciparum MSP119 demonstrated that three intraperitoneal
(i.p.) inoculations of JS1 (total dose of 1.5 mg antibody)
effectively suppressed a lethal blood stage challenge infection
in mice transgenic for human FccRI (Figure 7A). However,
JS1 was nonprotective in nontransgenic littermates allowing
us to conclude that FccRI recruitment by this fully human
anti-MSP119 IgG1 is crucial for therapeutic effectiveness. A
simple neutralization of MSP119 function by some form of
steric hindrance is therefore insufﬁcient to bring about
protection by this human IgG1. As expected, human IgG1
(B10) recognizing MSP119 from P. yoelii was completely
ineffective at controlling parasitemias, conﬁrming that bind-
ing of transgenic FccRI by human IgG1 is insufﬁcient to
induce protection in the absence of speciﬁc high-afﬁnity
antigen binding (Figure 7A).
Further experiments with JS1 could show that a total dose
of as little as 0.75 mg of antibody could result in effective
parasite clearance (Figure 7B). Importantly, protection could
be reversed with passive administration of mAb 10.1 (Figure
7B), a mouse mAb that binds to human FccRI blocking the
human IgG1 binding site, and allowing us to conclude that
immune protection is crucially dependent on the presence of
the human FccRI transgene and not endogenous murine
FccRs. JS2 was equally effective at controlling malaria at the
higher Ab dose of 1.5 mg/animal but was unable to prevent
the development of parasitemia at lower doses (0.75 mg/
animal) suggesting that subtle differences in afﬁnity or ﬁne-
speciﬁcity can ultimately impact signiﬁcantly on in vivo
efﬁcacy (unpublished data). Such a prediction could not have
been envisaged from in vitro assays while conﬁrming the
importance of our in vivo model for screening antibodies
that otherwise appear promising from initial in vitro screens.
Although we were unable to detect free merozoites or
infected erythrocytes from FccRI transgenic animals treated
with JS1, we did notice that many circulating phagocytes with
classical monocyte type morphology contained Giemsa-
staining merozoites within their cytoplasm (Figure 7C versus
7D and 7E).
There was no observable difference in the ability of the
FccRI transgenic mice versus nontransgenic animals in rates
of clearance of human antibodies, work that has also recently
been conﬁrmed in animals lacking all FccRs, suggesting that
Figure 4. JS1 and JS2 Are Fully Functional Human Antibodies
(A) Human neutrophil-mediated phagocytosis of GST-PfMSP119 coated
fluorescent 1-lm microspheres by JS1. A control human IgG1 recogniz-
ing the homologous GST-MSP119 from P. yoelii was unable to opsonize
beads and no ingestion was observed. Phagocytosed beads (red) were
visualized in the cytoplasm of neutrophils (arrowed) whose nuclear DNA
was counterstained in blue by DAPI.
(B) Stimulation of neutrophil NADPH oxidative bursts using JS1 and JS2
attached to GST-MSP119-coated microtiter plates. Chemiluminescence
(CL; arbitary units) was induced by anti-PfMSP119 human IgG1 JS1 (§),
JS2 (*), human IgA1 (&), or no antibody (n). All antibodies at 13 107 M.
Data are presented as mean arbitary units from duplicate wells with
neutrophils from a single donor.
doi:10.1371/journal.ppat.0030072.g004
Figure 5. Inhibition of Binding of mAbs 12.10 and 12.8 by Fully Human
Anti-MSP119 IgG1s (JS1 and JS2) by Competition ELISA
The binding of 12.8 is reduced by over 60% and the binding by 12.10
reduced by 30% suggesting that JS1 and JS2 compete with mAbs 12.8
and 12.10 for similar or overlapping epitopes. mAb 12.8, JS1, and JS2
were used at 0.5 lg/ml and mAb 12.10 at 0.05 lg/ml. Similar results were
also observed when saturating concentrations of antibodies were used.
doi:10.1371/journal.ppat.0030072.g005
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the neonatal FcR is wholly responsible for the kinetics of
clearance (unpublished data).
Discussion
We describe the development of the ﬁrst fully human IgG1
with speciﬁcity for an epitope on MSP119 from P. falciparum,
for dissecting human FcR mechanisms involved in immunity
to human malaria. These antibodies may also be employed in
the clinic as therapeutically useful entities. These novel
reagents were generated through cloning of human Ig
variable domains from human combinatorial phage display
libraries derived from malaria immune Gambians and their
engraftment onto human constant region genes, for expres-
sion in mammalian cells. Although fully human antibodies
have been generated to other P. falciparum antigens, the Fc-
receptors through which these antibodies confer their
protective effects have not been elucidated [27].
The engineered Abs recognized parasites in infected
erythrocytes and triggered potent human FccRI-mediated
protection in a novel Ab testing system involving the use of P.
berghei parasites transgenic for P. falciparum MSP119 and mice
transgenic for human FcRs. The human Abs bound to
nonidentical but overlapping residues in the ﬁrst epidermal
growth factor domain of P. falciparum MSP119 and with similar
afﬁnities to mouse mAbs, 12.10 and 12.8, already known to
inhibit erythrocyte invasion in vitro. Importantly, the
inability of human IgG1 to protect in nontransgenic mice
indicates that mere blocking of MSP119 function by some
form of steric hindrance or interference with MSP119
processing is insufﬁcient to bring about protection, and that
the presence of the Fc region is crucial, since this allows the
recruitment of FccRI-mediated parasite clearance. In con-
trast to mAb 12.10 and 12.8, neither JS1 nor JS2 could inhibit
MSP1 processing in vitro (unpublished data), suggesting that
their efﬁcacy in vivo is wholly dependent on Fc-mediated
pathways. It will be informative to determine if subcloning
the V genes onto alternative Fc scaffolds, such as IgG3 and
IgA, which having larger Fc regions and greater ﬂexibility to
the IgG1 created here, would confer processing inhibitory
activity. Interestingly, the JS1 and JS2 antibodies would be
classiﬁed as blocking antibodies that favor erythrocyte
invasion using an in vitro assay, but here the in vivo assay
shows that they are important in parasite destruction.
Since intact 12.10 and 12.8 can inhibit MSP1 processing
and invasion of erythrocytes in in vitro assays and Fabs and
F(ab9)2 cannot, it is likely that the Fc portion of the antibody
contributes in some way to this process. The Fc is of
signiﬁcant size (50 kDa) and is attached to the rest of the
antibody via a ﬂexible hinge that allows much wagging and
ﬂexibility in this region. Indeed the ﬂexibility of the Fc is
known to make an important contribution to function;
therefore, it is not inconceivable that it may interfere with
invasion by some form of steric hindrance of the merozoite.
An alternative explanation not requiring FcR-bearing effec-
tor cells, is that complement plays a role in this process since
only an intact antibody can activate the complement cascade
and this occurs through the Fc-region, while explaining the
lack of effect with Fabs or F(ab92). However, inhibition of
invasion assays are done with heat-inactivated serum or in the
presence of Albumax in the place of serum, suggesting that
complement does not play a role, at least in vitro.
These unique Abs allowed us to show a speciﬁc mechanism
of action in vivo, in experiments using mice transgenic for
human FccRI. Such in vivo experiments are not possible in
humans with P. falciparum malaria. Hence, recombinant
Table 1. The Location of Amino Acid Residues and the Modifications Made within MSP119 and Their Effect on the Binding by Fully
Human IgG1 (JS1 and JS2) or Previously Characterized Mouse mAbs 12.8 and 12.10
Position Wild-Type Mutant Binding by ELISA/Immunoblotting Binding of JS1 by SPR Analysis
mAb 12.8 mAb 12.10 JS1 (c1) JS2 (e9) ;KA(1/M) ;ka(1/Ms) ;kd(1/s)
WT   þþ þþ þþ þþ 3.94E þ 07 4.40E þ 03 1.12E-04
GST         
12 C I   þþ þþ 2.62E þ 07 6.74E þ 03 2.57E-04
28 C W       
20 R E þ þþ þ þ   
33 N I þþ þþ þ þ   
40 K I þ þþ þ þ 2.58E þ 07 4.13E þ 03 1.60E-04
29 K S þ þþ þ þ 1.51E þ 07 4.82E þ 03 3.20E-04
39 N T þþ þþ þ þ 6.28E þ 07 7.53E þ 03 1.20E-04
32 L R þþ þþ þþ þþ 8.70E þ 06 2.23E þ 03 2.56E-04
36 Q G þþ þþ þþ þþ 7.46E þ 06 1.63E þ 03 2.24E-04
37 E I þþ þþ þþ þþ 2.01E þ 07 4.33E þ 03 2.16E-04
53 N R þþ þþ þþ þþ 6.65E þ 06 2.57E þ 03 3.86E-04
12 þ 28 C/C I/Y       
34 þ 39 Y/N S/N þþ þþ þ þ 1.18E þ 07 2.45E þ 04 2.07E-04
43 þ 48 E/T L/I þþ þþ þþ þþ 8.68E þ 06 4.52E þ 03 5.21E-04
47 þ 48 P/T S/K þþ þþ þþ þþ 9.00E þ 06 3.46E þ 03 3.84E-04
27 þ 31 þ 34 þ 43 E/L/Y/E Y/R/S/L þþ þþ þþ þþ 7.35E þ 07 7.72E þ 03 1.15E-04
15 þ 27 þ 31 þ 43 N/E/L/E R/Y/R/L þþ þþ þþ þþ 5.54E þ 06 4.26E þ 03 7.41E-04
Recombinant GST-MSP119 with single or multiple amino acid substitutions at the positions indicated were used in ELISAs or immunoblotting with either JS1 or JS2. For SPR analysis, JS1
and JS2 were amine-coupled to flow cells 1 and 2, respectively, on a CM5 chip. Individual mutant fusion proteins of MSP119 were all injected at 2,500 nM and dissociation data collected.
Data from a Biacore X machine were analyzed using BIAevaluation software. þþ, strong binding;þ, binding;, no binding.
doi:10.1371/journal.ppat.0030072.t001
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human Abs engineered as described will be useful in
correlating particular epitopes on MSP119 with protective
immunity, as an aid to vaccine design, and will form the bases
of effective in vivo assays prior to clinical trials in humans.
Until now, work on human malaria parasites has made use of
polyclonal Abs puriﬁed from immune sera in neutralization
tests in vitro [18,19]. These antibody-dependent cellular
inhibition experiments are technically demanding and far
from optimal since sera contain a mixture of Abs, some with
inappropriate speciﬁcities (such as blocking Abs) and the
potential to trigger inhibitory FcR through intracellular
immunoreceptor tyrosine inhibition motif signaling. The
recombinant antibodies described herein are of a deﬁned
class and speciﬁcity and offer reproducible standards for such
assays in an in vivo system, a model that has hitherto not been
possible. The P. berghei mouse transgenic combination is a
good model for P. falciparum in humans since mouse IgG2a
binds with similar afﬁnity to human monocytes as human
IgG1, indicating that the transgenic receptor would be fully
occupied with mouse IgG2a in vivo and accurately reﬂecting
the situation in humans with IgG1 [28]. We believe that
because of the obvious limitations to primate and SCID
mouse studies, the transgenic approach described here is the
best current model in which to address human antibody
efﬁcacy and function.
Although Abs (in particular of the IgG1 and IgG3 classes)
from clinically immune individuals are without question
involved in immunity to malaria, the role of their cognate
FcRs has been investigated less thoroughly. FccRI expression
in these transgenic mice is limited to cells of the myeloid
lineage, including monocytes and dendritic cells and can be
upregulated by several cytokines including IL-10 and IFN-c,
both of which are implicated in immunity to malaria [29,30].
Previous work has highlighted monocytes in Ab-dependent
killing of P. falciparum asexual blood stages and implicated the
involvement of FccRII and FccRIII [18]. From a therapeutic
bioavailability standpoint triggering FccRII may not be ideal.
This is because both IgG1 and IgG3 can bind FccRs on cells
that do not directly kill parasites, including platelets, B cells,
endothelial cells, and even placental tissue, resulting in the
triggering of inhibitory FccRII receptors [4,5]. This might
beneﬁt the parasite, analogous to the effect on tumor cell
growth, in which passively administered anti-tumor Abs
enhanced tumor cell growth through FccRIIb [31]. That this
is indeed the case for malaria has recently been shown in an
elegant study in FccRIIb-deﬁcient mice, which have increased
clearance of Plasmodium chabaudi malaria and develop less
severe disease [32]. The same study went on to show that
polymorphic variants of human FccRIIb resulting in loss-of-
function are common in African individuals who also show
enhanced phagocytosis of parasites. Unfortunately, this study
used pooled immune serum and whole parasites, and the
contribution of individual IgG subclasses and the antigens
driving FccRIIb signaling could not be investigated. The
epitope-speciﬁc reagents described in this study would allow
these questions to be answered for fully human antibodies.
For example, we are in the process of mutating our anti-
MSP119 human IgG1s to make more potent antimalarial
antibodies by changing residues in the Fc that optimize
binding to the activatory receptors, including FccRI, at the
expense of binding to the FccRIIb inhibitory receptor [33].
Merozoite killing can also be mediated by neutrophils
[present study and 24,34]. Neutrophils are the most populous
leucocyte in blood and can express FccRI on activation with
IFN-c or G-CSF and targeting Candida albicans toward
neutrophil FccRI results in potent fungicidal activity in vivo
[35,36]. However, we do not observe any increase in
expression of the FccRI transgene on neutrophils from
animals infected with malaria parasites and therefore con-
clude that protective immunity manifested by this IgG1 is
mediated through monocytes (unpublished data and Figure
7).
It is known that the a-chain of FccRI can mediate
protective signaling events either through the common a-
chain or via Periplakin [17]. The availability of human FccRI-
transgenic animals deﬁcient in Periplakin will permit the
delineation of which signaling pathway is important in
protection to malaria. FccRI represents the only FccR with
a well-documented capacity to facilitate immunological
memory in vivo [37,38]. This may be crucial in the context
of malaria where the inability to induce or maintain long-
term memory responses is likely to pose major problems for
the development of effective vaccines [39].
Although no crystal structure exists for the interaction of
human FccRI with IgG1, the location has been inferred by
comparison with known structures for the association of IgG1
with FccRIII [40]. Such analyses consistently highlight an
extended hydrophobic area formed at the interface between
Figure 6. Epitope Mapping of JS1 and JS2 Binding Sites
Shows the location in the three-dimensional model of P. falciparum
MSP119 of residues in the first epidermal growth factor domain, which on
mutation affect binding by JS1 or JS2. Mutation of Cys28 shown in red
completely ablated binding of both mAbs (12.10 and 12.8) and JS1 or
JS2. Mutation of the partnering Cys12, also shown in red, while ablating
binding by the murine mAbs, had no effect on the binding by JS1 or JS2.
Arg20 and Asn33 in salmon had intermediate effects on binding as
determined by SPR analysis when mutated to more neutral or negatively
charged side-chains (see Table 1). Three further substitutions at Lys40,
Lys29, and Asn39 seen in brown had minor effects on binding when the
interaction was studied by ELISA. The model of P. falciparum MSP119 was
generated by PyMol using atomic coordinates available from NCBI under
accession number PDB: 1CEJ.
doi:10.1371/journal.ppat.0030072.g006
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the two N-terminal domains with contacting residues within
the D1/D2 connector, the B/C, C/E, and F/G loops of the EC2
domain. This region shows great variability between the
membrane-anchored version of FccRI, encoded by FccRIa,
and the FccRIb and FccRIc genes which are predicted to
encode secreted forms that suggest differences in ability to
bind IgG1. The role of these variant genes in malaria is
unknown. Although polymorphisms in FccRIIa, FccRIIIb, and
more recently FccRIIb, have been implicated in susceptibility
to severe malaria, no associations with FccRIa, or its
associating subunits, have yet been made [32,41–43]. It will
be important to determine if our fully human IgG1s are also
protective in mice transgenic for other human FccRs,
including FccRIIa.
By searching single nucleotide polymorphism (http://www.
ncbi.nlm.nih.gov/SNP) and trace databases, we identiﬁed
Figure 7. Course of a P. falciparum MSP119 Transgenic P. berghei Infection in Mice
(A) Groups of 2–3 FccRI transgenic (Tg) or nontransgenic (NTg) littermates were injected i.p. with a total dose of 1.5 mg fully human anti–P. falciparum
MSP119 IgG1 (JS1), an irrelevant human IgG1 (B10) recognizing MSP119 from P. yoelii or PBS. Similar results were obtained in two independent
experiments. **Only groups of mice given JS1 in the FccRI Tg were significantly different to all the other control groups with a p, 0.01. , death of mice.
(B) Repeat experiment in FccRI Tr animals using a lower total dose (0.75 mg) of JS1. Coadministration of the blocking mAb 10.1 specific for the IgG1
binding site on human FccRI abrogates the protection mediated by the passively administered JS1 antibody. Each point represents the geometric mean
parasitemia of mice in each group at the time after i.p. challenge with 5,000 parasitized erythrocytes. Only those animals receiving the fully human anti–
P. falciparum MSP119 IgG1 Ab in a human FccRI background survived an otherwise lethal infection; all the mice in the other groups with high
parasitemias were killed on either day 7 or 8. Similar results were obtained in two independent experiments. **Only groups of mice given JS1 in the
FccRI Tg were significantly different to all the other control groups with a p , 0.01. , death of mice.
(C–E)3100 magnification of Giemsa-stained smears of blood taken from control animals (C) and FccRI Tg animals treated with JS1 (D and E). Note the
presence of phagocytosed merozoites within the cytoplasm of cells displaying mononuclear morphology (arrow).
doi:10.1371/journal.ppat.0030072.g007
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FccRIa-speciﬁc polymorphic residues both in this region of
EC2 and in the cytoplasmic signaling domain that might
affect the outcome of malaria in human populations. By
creating mice transgenic for these variants, our humanized
model for P. falciparum malaria provides an opportunity for
testing experimentally and in vivo the effect of these
polymorphisms on the efﬁcacy of antibody function in
relation to malaria. The ability to predict how antibodies
will work in groups of patients with particular FccR
polymorphisms would allow targeted and tailored therapy
for these expensive reagents.
A clearer understanding of the role for individual FccRs in
malaria immunity is vital if Abs are to be used successfully as
therapeutic entities. Although human anti-MSP119 IgG1 is
clearly effective in passive immunization, its usefulness
remains to be tested in rodents or humans with already
well-established parasitemias. That they have the potential to
be extremely useful in such settings is supported by proof-of-
principle studies showing that passive transfer of polyclonal
IgG can reduce existing parasitemias in children and adults
[2,44].
A potential drawback to using IgG1 for malaria therapy in
humans is the high level of nonspeciﬁc IgG1 in the
hypogammaglobulinemia induced shortly after infection
[4,5,45]. Such Abs might compete with passively administered
IgG1 for FccRI occupancy, and therefore phagocyte recruit-
ment. The presence of pre-existing IgG may explain why large
doses of Ab have been required to neutralize parasites both in
vitro and in vivo [46]. Extrapolating to humans, the effective
dose of 0.75 mg/animal seen with JS1 compares well with the
required dosage of Palivizumab (15–75 mg/kg) known to
protect at-risk infants from infection with respiratory
syncytial virus [47]. A potential solution would be to engineer
increased afﬁnity for FccRI into our anti-MSP119 IgG1, for
example, by introducing more hydrophobic residues in place
of Leu235, Pro329, and Leu328 that would bind to FccRI in
preference to pre-existing IgGs, thus facilitating the use of
lower dosages [40].
Given increasing problems with resistance to antimalarial
drugs, a vaccine against malaria has become the ultimate goal.
Unfortunately, its development has been beset with problems,
and alternative strategies to treat malaria are urgently sought.
Here we have shown that the passive delivery of recombinant
Abs should be considered important adjuncts to more
traditional vaccine approaches, since Abs have the potential
to act both as therapies and as vehicles for the optimal
delivery of antigens in vaccination.
Materials and Methods
Phage libraries and selection procedures. Two phage-display
combinatorial immune antibody libraries were created from periph-
eral blood mononuclear leucocytes derived from 20 Gambian donors
during the dry season (March 1997 library, low prevalence of clinical
malaria) or at the end of the wet season (October 1997 library, high
prevalence of clinical malaria). For this study, informed consent was
obtained with guidelines of the Gambian Ministry of Health and the
Medical Research Council, whose ethical review committees ap-
proved all protocols. From these, ten donors were selected at random
on the basis of previously noted high levels of anti-MSP1 IgG for
library construction. The scFv libraries were constructed using
standard sets of primers from pooled total RNA obtained from
peripheral blood monocytes as described [20,48]. scFvs from the
heavy- and light-chain repertoires were cloned sequentially into
pHEN1H6 upstream of hexa-HIS and c-myc tags via SﬁI/NotI
restriction sites. The phage libraries were panned for binders using
immunotubes (Nunc, Maxisorp, http://www.nuncbrand.com) and
coated with recombinant MSP119-GST [49]. Approximately 1 3 10
14
phage from each of the two libraries were blocked in PBS containing
18% (w/v) skimmed milk powder and 100 lg/ml GST to prevent
selection of anti-GST scFvs during panning, prior to addition to the
coated immunotubes at 37 8C for 1 h. Bound phage were eluted into
100 mM triethylamine (pH 11.0), neutralized with 1 M Tris-HCl (pH
7.4), and then allowed to infect Escherichia coli TG1 host cells for
ampliﬁcation. After three further rounds of binding and ampliﬁca-
tion, 96 single clones were screened for binding to MSP119 by: (a)
direct ELISAs, (b) competition ELISAs with mAb 12.8 and 12.10,
known to be potent inhibitors of erythrocyte invasion in vitro, (c) IFA
to acetone-ﬁxed P. falciparum–infected erythrocytes, and (d) immuno-
blotting, all as described previously [21–24].
Construction of human antibodies. The VH genes derived from
scFv clones c1 and e9 were ampliﬁed by PCR using the following pairs
of forward (59ACAGGCGCGCACTCCGAGGTGCAGCTG-39) and
reverse (59ACCTGAGGAGACGGTGACCAGGGT-39) primers and
subcloned as BssHII/BstEII fragments into pVHExpress vectors,
upstream of the c1 constant region. VL genes were ampliﬁed using
sequence speciﬁc forward (c1, 59-GGCGTGCACTCCGATATTGT-
GATGACCCAG-39 and e9, 59-GGCGTGCACTCCGATGTTGTGAT-
GACTCAG-39) and reverse primers (59-GATCTCGAGACTCACG-
TTTGATCTCCA-39) as an ApaLI/XhoI fragment into pVKExpress
upstream of the human j gene [24,50]. Chinese hamster ovary (CHO)-
K1 cells were transfected with corresponding heavy- and light-chain
plasmids and positive clones secreting MSP119-speciﬁc IgG1 detected
by ELISA or immunoblotting using goat anti-human IgG conjugated
to horseradish peroxidase as described previously [24]. Two fully
human antibodies were produced, JS1 and JS2, derived from scFvs c1
and e9, respectively. From large-scale cultures of both JS1 and JS2,
human IgG1 was puriﬁed on HiTrap protein G-Sepharose (GE
Healthcare, http://www.gehealthcare.com) by FPLC. The integrity and
purity of the antibodies was veriﬁed on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels.
Antigen binding and invasion–inhibitory assays. For direct ELISAs,
scFv supernatants from individual clones were added to wells of a
microtiter plate (Nunc, Maxisorp) coated with MSP119-GST (diluted
to 1 lg/ml in coating buffer) after incubation in blocking solution
(phosphate buffered saline/3% milk powder). The scFvs were allowed
to bind for 1 h at 37 8C before three washes in PBS/0.1% Tween-20
and three further washes in PBS. 100 ll of 9E10 anti-c-myc hybridoma
supernatant was added to each well. After 1 h the plate was washed as
above and 100 ll of a 1/5,000 dilution peroxidase-conjugated goat
anti-mouse antibody (Jackson ImmunoResearch Laboratory, http://
www.jacksonimmuno.com) in blocking solution was added [20]. After
1 h the plate was washed as before and developed with Neogen K-
BLUE substrate (http://www.neogen.com). For western blotting, T9/96
or FCB-1 P. falciparum merozoites were boiled in nonreducing sample
buffer and extracts loaded into wells of a 15% SDS-PAGE gel prior to
transfer to nitrocellulose membranes [20]. The membrane was
incubated in blocking solution for 2 h before adding polyclonal scFv
at 1 lg/ml for 1 h. The membrane was washed three times with PBS/
0.1% Tween-20 and then incubated with 9E10 supernatant for 1 h on
a rotating platform. A 1:25,000 dilution of peroxidase-conjugated
goat anti-mouse antibody in blocking solution was added and
incubated for 1 h followed by washes as above [20]. Membranes were
developed using ECL chemiluminescent detection system (GE
Healthcare). Selected Ni-NTA puriﬁed or polyclonal scFvs and intact
antibodies were tested for their ability to bind acetone-ﬁxed T9/96,
FCB-1, and 3D7 P. falciparum or the P. berghei transgenic for P.
falciparum MSP119 (PbPfM19) by IFA as described previously
[20,24,25]. Invasion and processing assays were carried out according
to previously published protocols [21].
Epitope mapping. A number of approaches were used to map the
antigenic structures recognized by the V genes cloned from scFvs c1
and e9. A competition ELISA was designed to determine if scFvs or
intact Abs could compete with mAbs 12.8 and 12.10 for binding sites
on the MSP119 molecule. After coating in pre-blocked scFv or JS1/JS2
and washed as above, mAb 12.8 or 12.10 (0.5 lg and 0.05 lg/ml,
respectively) diluted in blocking solution were allowed to bind.
Bound mAb was then detected as described above [20]. A second
approach, combining ELISAs, western blotting, and SPR analysis took
advantage of an extensive panel of recombinant MSP119 mutants
derived by site-directed mutagenesis and used in an earlier study to
map both inhibitory and blocking mAbs [26]. For a quantitative
comparison of binding, human IgG1s (JS1 or JS2) were amine-
coupled to each ﬂow cell of a CM5 sensor chip. 2,500 nM of each
MSP119 mutant was then injected over each antibody and association
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and dissociation observed. Data from a BIAcore X machine were
analyzed using BIAevaluation 3.0 software. Antibody binding to the
panel of mutants was scored as follows: ‘‘þþ’’ indicates approximately
the same amount of antibody binding to the mutant MSP119 as to
wild-type, ‘‘þ’’ indicates reduced binding to the mutant compared to
wild-type, and ‘‘’’ indicates no detectable antibody binding to the
mutant protein.
Respiratory burst and phagocytosis assays. A chemiluminescence-
based neutrophil respiratory burst assay was conducted on plates
coated with recombinant GST-PfMSP119 at 10 lg mL
1 as previously
described [24]. 1 lm red ﬂuorescent carboxylate-modiﬁed micro-
spheres (Molecular Probes, http://probes.invitrogen.com) were cova-
lently coupled with GST-PfMSP119 using 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide, hydrochloride (EDAC) as per
manufacturer’s instructions. 7.23 104 beads were coated with 100 lg/
ml of each antibody in PBS/10% FCS. After three washes, beads were
resuspended in a ﬁnal volume of 100 ll containing 5 3 104
neutrophils puriﬁed as previously described [24]. Cells and beads
were gently pelleted at 1,200 rpm and incubated for 30 min at 37 8C.
Cells were then gently resuspended and smeared onto glass slides and
allowed to dry prior to mounting in ProLong Gold antifade reagent
with DAPI (Invitrogen, http://www.invitrogen.com). Phagocytosis was
observed by immunoﬂuorescence microscopy (Zeiss Axioskop 40,
http://www.zeiss.com).
Passive immunization and parasite challenge. Because of the lack
of an animal model for P. falciparum, human FccRI transgenic mice
have been developed that exhibit similar FccRI cell distribution and
expression patterns as in humans [29]. Tg Balb/c3 Balb/c F1 mice 9-
to 12-wk-old and bred under speciﬁc pathogen-free conditions were
used. Nontransgenic littermates served as controls. Mice were
screened for FccRI expression by PCR of whole blood using forward
(59 AGATTTCACTGCTCCCACCA-39) and reverse (59 CACTTGCC-
CATCAACTGGA-39) primers for human CD64 and by analysis of
lysed whole blood on a FAC-Scan with FITC-conjugated anti-human
FccRI (unpublished data). Antibodies (0.25 or 0.5 mg/injection
depending on experiment) or blocking mAb 10.1 (at 50 lg/injection,
Serotec, http://www.ab-direct.com) were administered i.p. on day 1,
day 0, and day þ1 with respect to parasite challenge. Parasitized
erythrocytes (5,000/mouse) derived from passaged mice infected with
P. berghei parasites transgenic for P. falciparum MSP119 were injected
i.p. at least 3 h after antibody treatment on day 0 as previously
described [24,25]. Parasitemia was assessed daily on Giemsa reagent-
stained blood smears. Differences between groups were analyzed over
two replicate experiments using the Mann Whitney test. A p-value ,
0.01 was considered signiﬁcant. All animal experiments were
approved by the Home Ofﬁce and performed in accordance with
United Kingdom guidelines and regulations (PPL40/2753).
Acknowledgments
This paper is dedicated to the late Dr. Jonathan Chappel. We thank
Eilish Cullen, Olivier Leger, Alison Levy, Margaret Cronin, Keith
Ansell, and Katy Kettleborough in the Medical Research Council
Collaborative Centre (MRC Technology) and Irene Ling, Muni
Grainger, and Terry Scott-Finnigan in the Division of Parasitology
at the National Institute for Medical Research. We would especially
like to thank Margaret Pinder, Bolong Jaiteh, Momodou Sanyang, and
the people of the village of Brefet in the Gambia for their assistance
in enabling us to obtain blood donations. We thank Dr. Karen
Bunting for help with molecular modeling of MSP119 and Dr. Phil
Buckle at Biacore for elucidation of afﬁnity data. We thank the
Medical Research Council and the European Union for supporting
our work.
Author contributions. AAH and RJP share senior authorship. RSM,
JS, TS, and ML performed all animal experiments, Biacore analysis,
generation of Abs, and ELISAs. RMJ, JCC, and TSJ designed and
constructed the phage libraries and contributed to discussion. JG
conducted inhibition of processing assays. MvE, JHWL, and JvdW
provided transgenic animals and important critique. TFdKW and
BSC provided transgenic parasites, contributed IFA data, and read
many drafts. AAH and RJP conceived and designed the overall study,
provided laboratory facilities, and wrote the paper.
Funding. This study was funded by a Medical Research Council
Career Establishment Award (G0300145) and a European Union
Marie Curie Excellence Grant, Antibody Immunotherapy for Malaria
(MEXT-CT-2003–509670) to RJP, and a ROPA (Realizing Our
Potential Award) to AAH.
Competing interests. The authors have declared that no competing
interests exist.
References
1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI, et al. (2005) The global
distribution of clinical episodes of Plasmodium falciparum malaria. Nature
434: 214–217.
2. Cohen S, McGregor IA, Carrington S (1961) Gamma-globulin and acquired
immunity to human malaria. Nature 192: 733–737.
3. Good MF, Kaslow DC, Miller LH (1998) Pathways and strategies for
developing a malaria blood-stage vaccine. Annu Rev Immunol 16: 57–87.
4. Pleass RJ, Holder AA (2005) Antibody-based therapies for malaria. Nat Rev
Micro 3: 893–899.
5. Shi J, McIntosh RS, Pleass RJ (2005) Antibody and Fc-receptor-based
therapeutics for malaria. Clin Sci 110: 11–19.
6. O’Donnell RA, Saul A, Cowman AF, Crabb BS (2000) Functional
conservation of the malaria vaccine antigen MSP119 across distantly
related Plasmodium species. Nat Med 6: 91–95.
7. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, et al. (2002)
A proteomic view of the Plasmodium falciparum life cycle. Nature 419: 520–
526.
8. O’Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, et al.
(2001) Antibodies against merozoite surface protein (MSP119) are a major
component of the invasion-inhibitory response in individuals immune to
malaria. J Exp Med 193: 1403–1412.
9. Martinelli A, Cheesman S, Hunt P, Cullerton R, Raza A, et al. (2005) A
genetic approach to the de novo identiﬁcation of targets of strain-speciﬁc
immunity in malaria parasites. Proc Natl Acad Sci U S A 102: 814–819.
10. Yoneto T, Waki S, Takai T (2001) A critical role of Fc receptor-mediated
antibody-dependent phagocytosis in the host resistance to blood stage
Plasmodium berghei XAT infection. J Immunol 166: 6236–6241.
11. Rotman HL, Daly TM, Clynes R, Long CA (1998) Fc receptors are not
required for Ab-mediated protection against lethal malaria challenge in a
mouse model. J Immunol 161: 1908–1912.
12. Yuan R, Clynes R, Oh J, Ravetch JV, Scharff MD (1998) Ab-mediated
modulation of Cryptococcus neoformans infection is dependent on distinct Fc
receptor functions and IgG subclasses. J Exp Med 187: 641–648.
13. Gavin AL, Barnes N, Dijstelbloem HM, Hogarth PM (1998) Identiﬁcation of
the mouse IgG3 receptor: Implications for Ab effector function at the
interface between innate and adaptive immunity. J Immunol 160: 20–23.
14. Ioan-Facsinay A, de Kimpse SJ, Hellwig SM, van Lent PL, Hofhuis FM, et al.
(2002) FcgammaRI (CD64) contributes substantially to severity of arthritis,
hypersensitivity responses, and protection from bacterial infection.
Immunity 16: 391–402.
15. Barnes N, Gavin AL, Tan PS, Mottram P, Koentgen F, et al. (2002)
FcgammaRI-deﬁcient mice show multiple alterations to inﬂammatory and
immune responses. Immunity 16: 379–389.
16. Van Vugt MJ, Kleijmeer MJ, Keler T, Zeelenberg I, van Dijk MA, et al. (1999)
The FcgammaRIa (CD64) ligand-binding chain triggers major histocom-
patibility complex class II Ag presentation independently of its associated
FcR gamma-chain. Blood 94: 808–817.
17. Beekman JM, Bakema JE, van de Winkel JG, Leusen JH (2004) Direct
interaction between FcgammaRI (CD64) and periplakin controls receptor
endocytosis and ligand-binding capacity. Proc Natl Acad Sci U S A 101:
10392–10397.
18. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P (1995) Mechanisms
underlying the monocyte-mediated Ab-dependent killing of Plasmodium
falciparum asexual blood stages. J Exp Med 182: 409–418.
19. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddi T,
Druilhe P (1990) Antibodies that protect humans against Plasmodium
falciparum blood stages do not on their own inhibit parasite growth and
invasion in vitro, but act in cooperation with monocytes. J Exp Med 172:
1633–1641.
20. Jennings RM (2001) Murine and human antibody responses to Plasmodium
falciparum merozoite surface protein 1. [PhD thesis]. London: National
Institute for Medical Research, London University College. 248 p.
21. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA (1990) A
single fragment of a malaria merozoite surface protein remains on the
parasite during red cell invasion and is the target of invasion-inhibitory
antibodies. J Exp Med 172: 379–322.
22. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ (1997) Abs that
inhibit malaria merozoite surface protein-1 processing and erythrocyte
invasion are blocked by naturally acquired human Abs. J Exp Med 186:
1689–1699.
23. Guevara Patino JA (1997) Antibody responses to, and the structure of
Plasmodium falciparum merozoite surface protein-1: A candidate malaria
vaccine antigen. [PhD thesis]. London: National Institute for Medical
Research. London University College. 387 p.
24. Pleass RJ, Ogun SA, McGuinness DH, van de Winkel JG, Holder AA, et al.
(2003) Novel antimalarial Abs highlight the importance of the Ab Fc region
in mediating protection. Blood 102: 4424–4430.
PLoS Pathogens | www.plospathogens.org May 2007 | Volume 3 | Issue 5 | e720657
Human FccRI Protects from Malaria
25. De Koning Ward TF, O’Donnell RA, Drew DR, Thomson R, Speed TP, et al.
(2003) A new rodent model to assess blood stage immunity to Plasmodium
falciparum antigen merozoite surface protein 119 reveals a protective role
for invasion inhibitory antibodies. J Exp Med 198: 869–875.
26. Uthaipibull C, Auﬁero B, Syed SE, Hansen B, Guevara Patino JA, et al.
(2001) Inhibitory and blocking monoclonal Ab epitopes on merozoite
surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol
307: 1381–1394.
27. Lundquist R, Nielsen LK, Jafarshad A, Soesoe D, Christensen LH, et al.
(2006) Human recombinant antibodies against Plasmodium falciparum
merozoite surface protein 3 cloned from peripheral blood leukocytes of
individuals with immunity to malaria demonstrate antiparasitic properties.
Infect Immun 74: 3222–3231.
28. Woof JM, Partridge LJ, Jefferis R, Burton DR (1986) Localization of the
monocyte-binding region on human immunoglobulin G. Mol Immunol 23:
319–330.
29. Heijnen IA, van Vugt MJ, Fanger NA, Graziano RF, de Wit TP, et al. (1996)
Antigen targeting to myeloid-speciﬁc human FccR1/CD64 triggers en-
hanced antibody responses in transgenic mice. J Clin Invest 97: 331–338.
30. Deo YM, Graziano RF, Repp R, van de Winkel JG (1997) Clinical
signiﬁcance of IgG Fc receptors and FccR directed therapies. Immunol
Today 18: 127–135.
31. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors
modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446.
32. Clatworthy MR, Willcocks L, Urban B, Langhorne J, Williams T, et al. (2007)
Systemic lupus erythrematosus-associated defects in the inhibitory recep-
tor FccRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A. In
press.
33. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, et al. (2006) Engineered
antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U
S A 103: 4005–4010.
34. Kumaratilake LM, Ferrante A, Jaeger T, Rzepezyk CM (1992) Effects of
cytokines, complement, and Ab on the neutrophil respiratory burst and
phagocytic response to Plasmodium falciparum merozoites. Infect Immun 60:
3731–3738.
35. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, et al. (1991) Neutrophils
express the high afﬁnity receptor for IgG (FccR1,CD64) after in vivo
application of recombinant human granulocyte colony-stimulating factor.
Blood 78: 885–891.
36. Van Spriel AB, van den Herik-Oudijk IE, van de Winkel JG (2001)
Neutrophil FccR1 as target for immunotherapy of invasive Candidiasis. J
Immunol 166: 7019–7022.
37. Honeychurch J, Tutt AL, Valerius T, Heijnen IA, van de Winkel JG, et al.
(2000) Therapeutic efﬁcacy of FccR1/CD64-directed bispeciﬁc antibodies in
B-cell lymphoma. Blood 96: 3544–3552.
38. Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van de Winkel JG, et al.
(2000) Targeting weak antigens to CD64 elicits potent humoral responses in
human CD64 transgenic mice. J Immunol 165: 6738–6742.
39. Struik SS, Riley EM (2004) Does malaria suffer from lack of memory?
Immunol Revs 201: 268–290.
40. Sonderman P, Kaiser J, Jacob U (2001) Molecular basis for immune complex
recognition: A comparison of Fc-receptor structures. J Mol Biol 309: 737–
749.
41. Shi YP, Nahlen BL, Kariuki S, Urdahl KB, McElroy PD, et al. (2001)
Fcgamma receptor IIa (CD32) polymorphism is associated with protection
of infants against high-density Plasmodium falciparum infection. VII. Asembo
Bay Cohort Project. J Infect Dis 184: 107–111.
42. Cooke GS, Aucan C, Walley AJ, Segal S, Greenwood BM, et al. (2003)
Association of Fcgamma receptor IIa (CD32) polymorphism with severe
malaria in West Africa. Am J Trop Med Hyg 69: 565–568.
43. Omi K, Ohashi J, Patarapotikul J, Hananantachai H, Naka I, et al. (2002)
Fcgamma receptor IIA and IIIB polymorphisms are associated with
susceptibility to cerebral malaria. Parasitol Int 51: 361–366.
44. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsupohasaisiddhi
T, Druilhe P (1990) Antibodies that protect humans against Plasmodium
falciparum blood stages do not on their own inhibit parasite growth and
invasion in vitro, but act in cooperation with monocytes. J Exp Med 172:
1633–1641.
45. Abele DC, Tobie JE, Hill GJ, Contacos PG, Evans CB (1965) Alterations in
serum proteins and 19S antibody production during the course of induced
malarial infection in man. Am J Trop Med Hyg 14: 191–197.
46. Saul A, Miller LH (2001) A robust neutralization test for Plasmodium
falciparum malaria. J Exp Med 193: 51–54.
47. Meissner HC, Long SS (2003) Revised indications for the use of Palivizumab
and RSV immune globulin intravenous for the prevention of RSV
infections. American Academy of Pediatrics Committee on Infectious
Diseases and Committee on Fetus and Newborn. Pediatrics 112: 1447–1452.
48. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Grifﬁths AD, et al.
(1991) By-passing immunization. Human antibodies from V-gene libraries
displayed on phage. J Mol Biol 222: 581–597.
49. Burghaus PA, Holder AA (1994) Expression of the 19-kDa carboxy-terminal
fragment of the Plasmodium falciparum merozoite surface protein-1 in
Escherichia coli as a correctly folded protein. Mol Biochem Parasitol 64: 165–
169.
50. Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, et al. (1997) An
integrated vector system for the eukaryotic expression of antibodies or
their fragments after selection from phage display libraries. Gene 187: 9–18.
PLoS Pathogens | www.plospathogens.org May 2007 | Volume 3 | Issue 5 | e720658
Human FccRI Protects from Malaria
